2025 Q4 -tulosraportti
58 päivää sitten
‧1 t 12 min
7,95 DKK/osake
Viimeisin osinko
4,94%Tuotto/v
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·3 t sittenI am down almost fifty percent in Novo, I can afford to stay invested, where will the share price be in 5-10 years? Does anyone have any good thoughts? Have a continued nice Easter everyone:-)
·15 min sittenThe past has no value, currently you get a return that at least corresponds to the return on a risky bond. Crucial is the belief in management and their products going forward, if yes then expect a return significantly above avg., risk taken into consideration. Therefore, I am long and long-term in Novo!
·4 t sittenI'm surprised that the newspaper Børsen has not reported on the study concerning Eli and Novo's pills. The market has apparently reacted well to the news that Novo's pill has advantages in several areas compared to Eli's. Perhaps I've overlooked something?
·1 t sittenhelgechr! Downgrades and stock price drops often get rapid attention, while positive news, that Novo Nordisk's rapid recovery of the dividend dip or insider buying gets less search interest. Børsen prioritizes negativity, as it drives readers. Novo has had a challenging period with a 65-70 percent fall since the 2024 peak, which dominates the story.
·5 t sittenKave01. No, agreed. Wegovy pill beats competitor in new Novo Nordisk studies Novo Nordisk's Wegovy pill was launched in the USA in early 2026. (Archive photo). (Photo: Søren Bidstrup/Ritzau Scanpix) Wegovy pill provides three percentage points greater weight loss than weight loss medication with orforglipron. Ritzau April 2, 2026 15:58 According to new studies from Novo Nordisk, patients on Wegovy pills achieved a weight loss of 3.0 to 3.2 percentage points greater than in patients taking weight loss medication with orforglipron. The Danish pharmaceutical company writes this in a press release. The American drug agency, FDA, on Wednesday approved Eli Lilly's weight loss pill Foundayo, which contains orforglipron. Foundayo is in direct competition with Novo Nordisk's Wegovy pill, which was launched in the USA in early 2026. Novo Nordisk's results will be presented at the annual obesity conference Obesity Medicine, the Danish pharmaceutical company states. house NEWS Read also: Apartments evacuated after partial collapse of gable The obesity conference will be held from April 10 to April 12 in the American state of California by the Obesity Medicine Association, an organization of doctors, nurses, and other healthcare professionals who work with the treatment of severe obesity. Both the substance semaglutide and orforglipron belong to the group of GLP-1 receptors. GLP-1 is a hormone that lowers blood sugar and inhibits appetite. According to the Danish Medicines Agency, headache, nausea, vomiting, diarrhea, constipation, abdominal pain, and fatigue are among the most common side effects of Wegovy, among others. According to Novo Nordisk's studies, there is a greater likelihood of stopping treatment with orforglipron due to side effects compared to the Wegovy pill with semaglutide. a jawbone remnant NEWS Read also: Archaeologists vacuumed Danish ship and found human jawbone Eli Lilly's pill will be available for shipment from April 6 through LillyDirect, where the drug is delivered directly to users bypassing traditional pharmacies. The pill will, according to the media MarketWire, be launched at a price of 149 dollars per month for the lowest dose for self-paying individuals. Americans covered by public health insurance Medicare can get the pill for 50 dollars per month. Novo Nordisk's pill also costs 149 dollars per month for self-paying users. From August 31, the price will increase to 199 dollars per month. For people covered by health insurance, the price starts at 25 dollars per month, according to MarketWire. /ritzau- ·5 t sittenCannot at all see/understand why so-called invest "experts" are sitting and babbling about Eli's pill having advantages. Where? Oral semaglutide 25 mg demonstrated significantly greater mean weight loss than orforglipron 36 mg in a population-adjusted indirect treatment comparison (ITC) using data from the OASIS 4 and ATTAIN-1 clinical trials1 Treatment with orforglipron 36 mg was associated with ~14 times higher odds of stopping medication due to GI adverse events versus oral semaglutide 25 mg in the ITC1 In a separate patient preference study, 84% of survey respondents favored the treatment profile similar to oral semaglutide 25 mg compared to that similar to orforglipron2
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
58 päivää sitten
‧1 t 12 min
7,95 DKK/osake
Viimeisin osinko
4,94%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·3 t sittenI am down almost fifty percent in Novo, I can afford to stay invested, where will the share price be in 5-10 years? Does anyone have any good thoughts? Have a continued nice Easter everyone:-)·15 min sittenThe past has no value, currently you get a return that at least corresponds to the return on a risky bond. Crucial is the belief in management and their products going forward, if yes then expect a return significantly above avg., risk taken into consideration. Therefore, I am long and long-term in Novo!
- ·4 t sittenI'm surprised that the newspaper Børsen has not reported on the study concerning Eli and Novo's pills. The market has apparently reacted well to the news that Novo's pill has advantages in several areas compared to Eli's. Perhaps I've overlooked something?·1 t sittenhelgechr! Downgrades and stock price drops often get rapid attention, while positive news, that Novo Nordisk's rapid recovery of the dividend dip or insider buying gets less search interest. Børsen prioritizes negativity, as it drives readers. Novo has had a challenging period with a 65-70 percent fall since the 2024 peak, which dominates the story.
- ·5 t sittenKave01. No, agreed. Wegovy pill beats competitor in new Novo Nordisk studies Novo Nordisk's Wegovy pill was launched in the USA in early 2026. (Archive photo). (Photo: Søren Bidstrup/Ritzau Scanpix) Wegovy pill provides three percentage points greater weight loss than weight loss medication with orforglipron. Ritzau April 2, 2026 15:58 According to new studies from Novo Nordisk, patients on Wegovy pills achieved a weight loss of 3.0 to 3.2 percentage points greater than in patients taking weight loss medication with orforglipron. The Danish pharmaceutical company writes this in a press release. The American drug agency, FDA, on Wednesday approved Eli Lilly's weight loss pill Foundayo, which contains orforglipron. Foundayo is in direct competition with Novo Nordisk's Wegovy pill, which was launched in the USA in early 2026. Novo Nordisk's results will be presented at the annual obesity conference Obesity Medicine, the Danish pharmaceutical company states. house NEWS Read also: Apartments evacuated after partial collapse of gable The obesity conference will be held from April 10 to April 12 in the American state of California by the Obesity Medicine Association, an organization of doctors, nurses, and other healthcare professionals who work with the treatment of severe obesity. Both the substance semaglutide and orforglipron belong to the group of GLP-1 receptors. GLP-1 is a hormone that lowers blood sugar and inhibits appetite. According to the Danish Medicines Agency, headache, nausea, vomiting, diarrhea, constipation, abdominal pain, and fatigue are among the most common side effects of Wegovy, among others. According to Novo Nordisk's studies, there is a greater likelihood of stopping treatment with orforglipron due to side effects compared to the Wegovy pill with semaglutide. a jawbone remnant NEWS Read also: Archaeologists vacuumed Danish ship and found human jawbone Eli Lilly's pill will be available for shipment from April 6 through LillyDirect, where the drug is delivered directly to users bypassing traditional pharmacies. The pill will, according to the media MarketWire, be launched at a price of 149 dollars per month for the lowest dose for self-paying individuals. Americans covered by public health insurance Medicare can get the pill for 50 dollars per month. Novo Nordisk's pill also costs 149 dollars per month for self-paying users. From August 31, the price will increase to 199 dollars per month. For people covered by health insurance, the price starts at 25 dollars per month, according to MarketWire. /ritzau
- ·5 t sittenCannot at all see/understand why so-called invest "experts" are sitting and babbling about Eli's pill having advantages. Where? Oral semaglutide 25 mg demonstrated significantly greater mean weight loss than orforglipron 36 mg in a population-adjusted indirect treatment comparison (ITC) using data from the OASIS 4 and ATTAIN-1 clinical trials1 Treatment with orforglipron 36 mg was associated with ~14 times higher odds of stopping medication due to GI adverse events versus oral semaglutide 25 mg in the ITC1 In a separate patient preference study, 84% of survey respondents favored the treatment profile similar to oral semaglutide 25 mg compared to that similar to orforglipron2
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 |
2025 Q4 -tulosraportti
58 päivää sitten
‧1 t 12 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 |
7,95 DKK/osake
Viimeisin osinko
4,94%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·3 t sittenI am down almost fifty percent in Novo, I can afford to stay invested, where will the share price be in 5-10 years? Does anyone have any good thoughts? Have a continued nice Easter everyone:-)·15 min sittenThe past has no value, currently you get a return that at least corresponds to the return on a risky bond. Crucial is the belief in management and their products going forward, if yes then expect a return significantly above avg., risk taken into consideration. Therefore, I am long and long-term in Novo!
- ·4 t sittenI'm surprised that the newspaper Børsen has not reported on the study concerning Eli and Novo's pills. The market has apparently reacted well to the news that Novo's pill has advantages in several areas compared to Eli's. Perhaps I've overlooked something?·1 t sittenhelgechr! Downgrades and stock price drops often get rapid attention, while positive news, that Novo Nordisk's rapid recovery of the dividend dip or insider buying gets less search interest. Børsen prioritizes negativity, as it drives readers. Novo has had a challenging period with a 65-70 percent fall since the 2024 peak, which dominates the story.
- ·5 t sittenKave01. No, agreed. Wegovy pill beats competitor in new Novo Nordisk studies Novo Nordisk's Wegovy pill was launched in the USA in early 2026. (Archive photo). (Photo: Søren Bidstrup/Ritzau Scanpix) Wegovy pill provides three percentage points greater weight loss than weight loss medication with orforglipron. Ritzau April 2, 2026 15:58 According to new studies from Novo Nordisk, patients on Wegovy pills achieved a weight loss of 3.0 to 3.2 percentage points greater than in patients taking weight loss medication with orforglipron. The Danish pharmaceutical company writes this in a press release. The American drug agency, FDA, on Wednesday approved Eli Lilly's weight loss pill Foundayo, which contains orforglipron. Foundayo is in direct competition with Novo Nordisk's Wegovy pill, which was launched in the USA in early 2026. Novo Nordisk's results will be presented at the annual obesity conference Obesity Medicine, the Danish pharmaceutical company states. house NEWS Read also: Apartments evacuated after partial collapse of gable The obesity conference will be held from April 10 to April 12 in the American state of California by the Obesity Medicine Association, an organization of doctors, nurses, and other healthcare professionals who work with the treatment of severe obesity. Both the substance semaglutide and orforglipron belong to the group of GLP-1 receptors. GLP-1 is a hormone that lowers blood sugar and inhibits appetite. According to the Danish Medicines Agency, headache, nausea, vomiting, diarrhea, constipation, abdominal pain, and fatigue are among the most common side effects of Wegovy, among others. According to Novo Nordisk's studies, there is a greater likelihood of stopping treatment with orforglipron due to side effects compared to the Wegovy pill with semaglutide. a jawbone remnant NEWS Read also: Archaeologists vacuumed Danish ship and found human jawbone Eli Lilly's pill will be available for shipment from April 6 through LillyDirect, where the drug is delivered directly to users bypassing traditional pharmacies. The pill will, according to the media MarketWire, be launched at a price of 149 dollars per month for the lowest dose for self-paying individuals. Americans covered by public health insurance Medicare can get the pill for 50 dollars per month. Novo Nordisk's pill also costs 149 dollars per month for self-paying users. From August 31, the price will increase to 199 dollars per month. For people covered by health insurance, the price starts at 25 dollars per month, according to MarketWire. /ritzau
- ·5 t sittenCannot at all see/understand why so-called invest "experts" are sitting and babbling about Eli's pill having advantages. Where? Oral semaglutide 25 mg demonstrated significantly greater mean weight loss than orforglipron 36 mg in a population-adjusted indirect treatment comparison (ITC) using data from the OASIS 4 and ATTAIN-1 clinical trials1 Treatment with orforglipron 36 mg was associated with ~14 times higher odds of stopping medication due to GI adverse events versus oral semaglutide 25 mg in the ITC1 In a separate patient preference study, 84% of survey respondents favored the treatment profile similar to oral semaglutide 25 mg compared to that similar to orforglipron2
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt